...
首页> 外文期刊>Expert opinion on therapeutic targets >Nuclear receptors as drug targets: new developments in coregulators, orphan receptors and major therapeutic areas.
【24h】

Nuclear receptors as drug targets: new developments in coregulators, orphan receptors and major therapeutic areas.

机译:核受体作为药物靶标:抑癌药,孤儿受体和主要治疗领域的新发展。

获取原文
获取原文并翻译 | 示例
           

摘要

Nuclear receptors (NRs) are ideal targets for drug discovery. Not only do they control a myriad of biological and disease processes, but they are also regulated by small lipophilic molecules that can be easily exchanged with a drug of choice. All 48 of the NR genes in the human genome have been identified, many of their structures have been solved and their ligands identified. Their mechanism of action has been elucidated and many of their target genes have been identified. Nonetheless, presentations at the recent conference sponsored by IBC Life Sciences indicated that, while many NRs already have marketable drugs, the latest tools in robotics, genomics, proteomics, and informatics are helping to identify more selective drugs.
机译:核受体(NRs)是药物发现的理想目标。它们不仅控制着无数的生物学和疾病过程,而且还受到亲脂性小分子的调节,这些亲脂性小分子可以很容易地与所选药物进行交换。已鉴定出人类基因组中的所有48个NR基因,其中许多结构已被解析,其配体也已被鉴定。他们的作用机理已经阐明,许多目标基因已经被鉴定。尽管如此,在由IBC Life Sciences赞助的最近一次会议上的演讲表明,尽管许多NRs已经拥有可销售的药物,但是机器人技术,基因组学,蛋白质组学和信息学方面的最新工具正在帮助鉴定更具选择性的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号